Explore
Trendline
Consumer Reports Identifies Top Bug Repellents for Summer 2026, Emphasizing Effectiveness and Safety
Consumer Reports Identifies Top Bug Repellents for Summer 2026, Emphasizing Effectiveness and Safety
Read More
Trendline
Researchers Develop Multifunctional MXene Coating for Anti-Icing and Self-Healing in Polar Environments
Researchers Develop Multifunctional MXene Coating for Anti-Icing and Self-Healing in Polar Environments
Read More
Trendline
New MXene Coating Offers Anti-Icing and Self-Healing for Metal Protection in Extreme Environments
New MXene Coating Offers Anti-Icing and Self-Healing for Metal Protection in Extreme Environments
Read More
Trendline
Poxel Reports Increased Revenue for Q1 2026 Amid TWYMEEG® Sales Growth in Japan
Poxel Reports Increased Revenue for Q1 2026 Amid TWYMEEG® Sales Growth in Japan
Read More
Trendline
Eli Lilly Acquires Engage Bio for $202 Million to Enhance Genetic Medicines Portfolio
Eli Lilly Acquires Engage Bio for $202 Million to Enhance Genetic Medicines Portfolio
Read More
Trendline
Bristol Myers Squibb Partners with Anthropic to Deploy AI Platform Claude
Bristol Myers Squibb Partners with Anthropic to Deploy AI Platform Claude
Read More
Trendline
OpenBind Launches AI Model for Drug Discovery with Extensive Dataset
OpenBind Launches AI Model for Drug Discovery with Extensive Dataset
Read More
Trendline
Autolus Therapeutics Reports Positive Gross Margin Amid Revenue Surge
Autolus Therapeutics Reports Positive Gross Margin Amid Revenue Surge
Read More
Trendline
Passkey Therapeutics Appoints New CMO to Advance Drug Combination Platform
Passkey Therapeutics Appoints New CMO to Advance Drug Combination Platform
Read More
Trendline
Opentrons Introduces Compliance Ready Software for Flex Lab Robots to Enhance Regulatory Adherence
Opentrons Introduces Compliance Ready Software for Flex Lab Robots to Enhance Regulatory Adherence
Read More
Trendline
Parabilis Biotech Files for IPO to Fund Cancer Drug Trials
Parabilis Biotech Files for IPO to Fund Cancer Drug Trials
Read More
Trendline
FDA Accepts ImmunityBio's Supplemental BLA for ANKTIVA Plus BCG in Bladder Cancer Treatment
FDA Accepts ImmunityBio's Supplemental BLA for ANKTIVA Plus BCG in Bladder Cancer Treatment
Read More